192 related articles for article (PubMed ID: 20378525)
1. The Post-JUPITER trial era and the cost of preventive medicine.
Papadopoulos VP
Hellenic J Cardiol; 2010; 51(2):187-8. PubMed ID: 20378525
[No Abstract] [Full Text] [Related]
2. The JUPITER Trial: responding to the critics.
Ridker PM; Glynn RJ
Am J Cardiol; 2010 Nov; 106(9):1351-6. PubMed ID: 21029837
[No Abstract] [Full Text] [Related]
3. [The JUPITER study].
Gaspardone A; Maseri A
G Ital Cardiol (Rome); 2009 May; 10(5):267-70. PubMed ID: 19537439
[No Abstract] [Full Text] [Related]
4. Clinical trial update II: Jupiter trial, rosuvastatin has greater efficacy in elderly populations.
Fricker J
Eur Heart J; 2009 Dec; 30(23):2821. PubMed ID: 19972644
[No Abstract] [Full Text] [Related]
5. JUPITER, rosuvastatin, and the European Medicines Agency.
Ridker PM; Glynn RJ
Lancet; 2010 Jun; 375(9731):2071. PubMed ID: 20494436
[No Abstract] [Full Text] [Related]
6. Is Jupiter also a god of primary prevention?
Accad M; Fred HL
Tex Heart Inst J; 2010; 37(1):6-7. PubMed ID: 20200621
[No Abstract] [Full Text] [Related]
7. [Comment from the cardiologic viewpoint].
Lüscher TF
Praxis (Bern 1994); 2009 Feb; 98(3):129-30. PubMed ID: 19180438
[No Abstract] [Full Text] [Related]
8. The Jupiter trial: key findings, controversies, and implications.
Nissen SE
Curr Cardiol Rep; 2009 Mar; 11(2):81-2. PubMed ID: 19236822
[No Abstract] [Full Text] [Related]
9. Jupiter to Earth: CRP promotes atherothrombosis.
Jialal I; Devaraj S
Metab Syndr Relat Disord; 2009 Feb; 7(1):1-3. PubMed ID: 19183073
[No Abstract] [Full Text] [Related]
10. [How to prolong life of patients at high cardiovascular risk. Features of rosuvastatin].
Drapkina OM; Korneeva ON
Kardiologiia; 2012; 52(8):89-92. PubMed ID: 23098406
[No Abstract] [Full Text] [Related]
11. Is hsCRP Back on Board? Implications from the JUPITER Trial.
Koenig W
Clin Chem; 2009 Feb; 55(2):216-8. PubMed ID: 19074517
[No Abstract] [Full Text] [Related]
12. JUPITER strikes earth.
Fuster V; Bansilal S
Nat Clin Pract Cardiovasc Med; 2009 Mar; 6(3):159. PubMed ID: 19234496
[No Abstract] [Full Text] [Related]
13. JUPITER clinical directions--polling results.
Kritek P; Campion EW
N Engl J Med; 2009 Mar; 360(10):e14. PubMed ID: 19264683
[No Abstract] [Full Text] [Related]
14. Rosuvastatin in patients with elevated C-reactive protein.
Koller MT; Bucher HC; Steyerberg EW
N Engl J Med; 2009 Mar; 360(10):1041; author reply 1041-2. PubMed ID: 19271276
[No Abstract] [Full Text] [Related]
15. Rosuvastatin and the JUPITER trial: critical appraisal of a lifeless planet in the galaxy of primary prevention.
López A; Wright JM
Int J Occup Environ Health; 2012; 18(1):70-8. PubMed ID: 22550699
[TBL] [Abstract][Full Text] [Related]
16. [JUPITER study, more reason to give statins as preventive measure - commentary].
Narkiewicz K
Kardiol Pol; 2009 Mar; 67(3):346-7. PubMed ID: 19469067
[No Abstract] [Full Text] [Related]
17. The conundrum of C-reactive protein as a risk marker for cardiovascular risk assessment: insight from EPIC-Norfolk and JUPITER.
Chapman MJ; Giral P; Barter PJ
Eur Heart J; 2013 May; 34(18):1318-20. PubMed ID: 23482520
[No Abstract] [Full Text] [Related]
18. The Jupiter trial--new territory for statins?
Wheeler DC
Nephrol Dial Transplant; 2009 Jul; 24(7):2036-7. PubMed ID: 19541666
[No Abstract] [Full Text] [Related]
19. [Lipid lowering by rosuvastatin: how do statins differ?].
Laufs U
Dtsch Med Wochenschr; 2015 Mar; 140(5):313. PubMed ID: 25734669
[No Abstract] [Full Text] [Related]
20. The JUPITER and AURORA clinical trials for rosuvastatin in special primary prevention populations: perspectives, outcomes, and consequences.
Narla V; Blaha MJ; Blumenthal RS; Michos ED
Vasc Health Risk Manag; 2009; 5():1033-42. PubMed ID: 20057896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
